Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fexuprazan-based Helicobacter pylori eradication therapy
KCT0008592Phase 2Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fexuprazan in Helicobacter pylori infection, sponsored by Daewoong Pharmaceutical. Started Mar 2024; status: completed.
02
Drugs
fexuprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on KCT0008592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008592.